P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT
Rattachement africain : de, it, dk, nl, be, es, fr, at, gb, tr, hu, cl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: There is a lack of consolidated data has resulted in a general skepticism on anti-SARS-CoV-2 fourth dose efficacy. As a consequence, only few individuals received a fourth dose, despite several data supports the low immunogenicity of anti-SARS-CoV-2 vaccine in pateints with hematological malignancies. Aims: We aim to report the clinical presentation and outcome of COVID-19 occurring in a cohort of HM patients who had previously received a fourth anti-SARS-CoV-2 vaccine dose registered in the EPICOVIDEHA registry. Methods: Any patient included in the EPICOVIDEHA registry was eligible as long as they could fulfill these criteria: a) active HM within the last five years before COVID-19 diagnosis, b) patients ≥18 years old, c) laboratory-based diagnosis of SARS-CoV-2 infection, and d) reception of a fourth anti-SARS-CoV-2 dose before COVID-19 diagnosis. Results: 6867 HM patients with SARS-CoV-2 infection have been registered in the EPICOVIDEHA registry. Of these, 51 (0.7%) were diagnosed with COVID-19 after having received a fourth vaccine dose. Most of those (30/51, 58.8%) were male; median age was 71 years (IQR 65-73) comprising only three patients below the age of 50 years. Twelve patients (12/51, 23.5%) did not present any baseline underlying conditions besides the HM. Lymphoproliferative malignancies were prevalent (47/51, 92%). Most patients had a controlled HM at the time of COVID-19 diagnosis (30, 58.8%). Patients received the fourth vaccine dose at a median of 32 days (IQR 13-54) before COVID-19 diagnosis, almost exclusively mRNA based (50/51, 98%). COVID-19 remained asymptomatic or mild in almost all cases (49/51, 96%), with only one case of critical infection (2%) requiring intensive care. Hospital admission rate was 47.1% with a median hospital stay of 9 days (IQR 5-14). Only 26 patients (51%) received a specific treatment for SARS-CoV-2, with almost all of them (18/26, 69.2%) receiving monoclonal antibodies. Patients were followed up for a median of 65 days (IQR 26-86) and only two died (3.9%) due to COVID-19. Summary/Conclusion: In conclusion, with the caution derived from the limited patient number and the intrinsic nature of this study, our data show favorable clinical presentation and outcome of breakthrough SARS-CoV2 infections in HM who previously received a fourth dose of anti-SARSCoV-2 vaccine. The data suggests that a second vaccine booster may be of particular importance to protect this particularly vulnerable patient population from severe or potentially life-threatening COVID-19. Keywords: Hematological malignancy, COVID-19, Infection, Vaccination
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT
- Date Crossref
- 01/08/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Cologne pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Cologne pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Copenhagen University Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Rigshospitalet pays non établi dans la noticeÉtablissement de santé
-
Admiraal De Ruyter Ziekenhuis pays non établi dans la noticeÉtablissement de santé
-
AZ Sint-Jan pays non établi dans la noticeÉtablissement de santé
-
Hospital Nuestra Señora de Alarcos pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario de Burgos pays non établi dans la noticeÉtablissement de santé
-
University Medical Center Groningen pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario La Paz pays non établi dans la noticeÉtablissement de santé
-
IRCCS Ospedale San Raffaele pays non établi dans la noticeÉtablissement de santé
University of Cologne, University Hospital Cologne et Istituti di Ricovero e Cura a Carattere Scientifico, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.